PMID- 36523727
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221221
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 14
IP  - 11
DP  - 2022 Nov
TI  - Role of Ertugliflozin in the Management of Diabetes Mellitus.
PG  - e31404
LID - 10.7759/cureus.31404 [doi]
LID - e31404
AB  - The novel oral sodium-glucose cotransporter-2 (SGLT2) inhibitor Ertugliflozin 
      (SteglatroTM) is introduced as a monotherapy or in conjunction with another 
      antidiabetic drug regimen for the treatment of type 2 diabetes mellitus 
      (T2DM).Additional safe and efficient treatment options for patients and 
      physicians are of utmost importance as the incidence of T2DM rises. As a 
      standalone therapy or an adjunctive treatment, ertugliflozin seems to be a 
      reliable and safe option.This narrative review seeks to report and analyze 
      ertugliflozin's effectiveness, safety, cardiovascular (CV), and renal outcomes in 
      T2DM. Various combinations of drugs and drug classes have been tried to reduce 
      mortality and comorbidities associated with the use of antidiabetic agents, 
      especially cardiogenic events and renal diseases. With the administration of 
      hypoglycemic drugs like ertugliflozin and the regulation of blood sugar levels, 
      the incidence of therapy-induced hypertension, obesity, and dose-related 
      hypoglycemia has been reduced to a significant extent. Additionally, 
      ertugliflozin prevents hypertension caused by prolonged antidiabetic drug intake, 
      which is advantageous for lowering the chances of end-stage cardiac events in 
      type 2 diabetic patients. As far as the renal safety profile of ertugliflozin is 
      concerned, it has been associated with the maintenance of eGFR (estimated 
      glomerular filtration rate) and a decreased UACR (urine albumin-to-creatinine 
      ratio) in patients with T2DM and coronary artery disease, which reduces the 
      incidence of renal adverse effects due to long-term medication. As a result of 
      common pathophysiological mechanisms, SGLT2 inhibitors represent a feasible 
      therapeutic option and are advantageous for patients with type 1 and type 2 DM in 
      terms of cardiovascular and renal outcomes.
CI  - Copyright (c) 2022, Totade et al.
FAU - Totade, Manisha
AU  - Totade M
AD  - Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical 
      Sciences, Wardha, IND.
FAU - Gaidhane, Shilpa A
AU  - Gaidhane SA
AD  - Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical 
      Sciences, Wardha, IND.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221112
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC9744393
OTO - NOTNLM
OT  - cardiovascular effects
OT  - diabetes mellitus
OT  - ertugliflozin
OT  - glycemic control
OT  - insulin
OT  - monotherapy
OT  - renal hypoglycemia
OT  - sglt2 inhibitor
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/12/17 06:00
MHDA- 2022/12/17 06:01
PMCR- 2022/11/12
CRDT- 2022/12/16 02:25
PHST- 2022/08/10 00:00 [received]
PHST- 2022/11/12 00:00 [accepted]
PHST- 2022/12/16 02:25 [entrez]
PHST- 2022/12/17 06:00 [pubmed]
PHST- 2022/12/17 06:01 [medline]
PHST- 2022/11/12 00:00 [pmc-release]
AID - 10.7759/cureus.31404 [doi]
PST - epublish
SO  - Cureus. 2022 Nov 12;14(11):e31404. doi: 10.7759/cureus.31404. eCollection 2022 
      Nov.